Citations

Clear

6273 citation(s) found for "To, Andrew".

A tale of three papers
Murie, J A, Sarr, M. G., Warshaw, Andrew L.

Mayo Clinic

British Journal of Surgery | November 17, 2006 | Volume: 93 | Issue: 12 | Pages: 1560-1562

10.1002/bjs.5642 | PMID 17115395 Get It

How Much Health Insurance Is Enough? Revisiting the Concept of Underinsurance
Blewett, Lynn A. , Beebe, Timothy J. , Ward, Andrew C.

Mayo Clinic

Medical Care Research and Review | November 13, 2006 | Volume: 63 | Issue: 6 | Pages: 663-700

10.1177/1077558706293634 | PMID 17099121 Get It

There is little consensus on what constitutes adequate health insurance coverage. The concept of a lack of adequate coverage, or underinsurance, is a matter of ongoing debate. A measure of adequate coverage is of critical importance as the nature of health insurance products evolves. Changes to health coverage include more direct out-of-pocket spending by consumers and a reduction of covered benefits. This article updates and extends an earlier review of underinsurance measurement published in 1993. We present a conceptual approach to measuring underinsurance and provide a review of the empirical findings obtained from the application of these approaches. A discussion of the limitations in the selection of a measurement approach includes a review of the extant data sources used. We recommend a national effort to develop a consistent approach to monitor changes in the economic and structural dimensions of health insurance coverage with a concerted effort to define and measure underinsurance.
First Prize: Long-Term Success of Antegrade Endopyelotomy Compared with Pyeloplasty at a Single Institution
DiMarco, David S., Gettman, Matthew T., McGee, Shawn M., Chow, George K. , LeRoy, Andrew J., Patterson, David E., Segura, Joseph W., Slezak, Jeff M.

Mayo Clinic

Journal of Endourology | November 9, 2006 | Volume: 20 | Issue: 10 | Pages: 707-712

10.1089/end.2006.20.707 | PMID 17094743 Get It

Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain
Liang, Winnie S. , Dunckley, Travis , Beach, Thomas G. , Grover, Andrew, Mastroeni, Diego , Walker, Douglas G. , Caselli, Richard J. , Kukull, Walter A. , McKeel, Daniel W., Morris, John C. , Hulette, Christine, Schmechel, Donald E., Alexander, Gene E. , Reiman, Eric M. , Rogers, Joseph, Stephan, Dietrich A. , Morris, John C

Mayo Clinic

Physiological Genomics | October 31, 2006 | Volume: 28 | Issue: 3 | Pages: 311-322

10.1152/physiolgenomics.00208.2006 | PMID 17077275 Get It

In this article, we have characterized and compared gene expression profiles from laser capture microdissected neurons in six functionally and anatomically distinct regions from clinically and histopathologically normal aged human brains. These regions, which are also known to be differentially vulnerable to the histopathological and metabolic features of Alzheimer’s disease (AD), include the entorhinal cortex and hippocampus (limbic and paralimbic areas vulnerable to early neurofibrillary tangle pathology in AD), posterior cingulate cortex (a paralimbic area vulnerable to early metabolic abnormalities in AD), temporal and prefrontal cortex (unimodal and heteromodal sensory association areas vulnerable to early neuritic plaque pathology in AD), and primary visual cortex (a primary sensory area relatively spared in early AD). These neuronal profiles will provide valuable reference information for future studies of the brain, in normal aging, AD and other neurological and psychiatric disorders.
Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR / ABL fusion to ass
Landstrom, Andrew P. , Ketterling, Rhett P. , Knudson, Ryan A., Tefferi, Ayalew , Landstrom, Andrew P , Ketterling, Rhett P

Mayo Clinic

Leukemia & Lymphoma | October 26, 2006 | Volume: 47 | Issue: 10 | Pages: 2055-2061

10.1080/10428190600783551 | PMID 17071476 Get It

PIK3CA Gene Mutations in Pediatric and Adult Glioblastoma Multiforme
Gallia, Gary L. , Rand, Vikki , Siu, I‐Mei, James, C. David , Marie, Suely Kazue Nagahashi , Oba‐Shinjo, Sueli Mieko , Carlotti, Carlos Gilberto , Caballero, Otávia L., Simpson, Andrew J.G., Brock, Malcolm V., Massion, Pierre P. , Carson, Benjamin S., Riggins, Gregory J. , Eberhart, Charles G.

Mayo Clinic

Molecular Cancer Research | October 18, 2006 | Volume: 4 | Issue: 10 | Pages: 709-714

10.1158/1541-7786.mcr-06-0172 | PMID 17050665 Get It

Abstract The phosphatidylinositol 3-kinases (PI3K) are a family of enzymes that relay important cellular growth control signals. Recently, a large-scale mutational analysis of eight PI3K and eight PI3K-like genes revealed somatic mutations in PIK3CA, which encodes the p110α catalytic subunit of class IA PI3K, in several types of cancer, including glioblastoma multiforme. In that report, 4 of 15 (27%) glioblastomas contained potentially oncogenic PIK3CA mutations. Subsequent studies, however, showed a significantly lower mutation rate ranging from 0% to 7%. Given this disparity and to address the relation of patient age to mutation frequency, we examined 10 exons of PIK3CA in 73 glioblastoma samples by PCR amplification followed by direct DNA sequencing. Overall, PIK3CA mutations were found in 11 (15%) samples, including several novel mutations. PIK3CA mutations were distributed in all sample types, with 18%, 9%, and 13% of primary tumors, xenografts, and cell lines containing mutations, respectively. Of the primary tumors, PIK3CA mutations were identified in 21% and 17% of pediatric and adult samples, respectively. No evidence of PIK3CA gene amplification was detected by quantitative real-time PCR in any of the samples. This study confirms that PIK3CA mutations occur in a significant number of human glioblastomas, further indicating that therapeutic targeting of this pathway in glioblastomas is of value. Moreover, this is the first study showing PIK3CA mutations in pediatric glioblastomas, thus providing a molecular target in this important pediatric malignancy. (Mol Cancer Res 2006;4(10):709–14)
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study
Richards, Susan , Chopra, Rajesh, Litzow, Mark R. , Buck, Georgina , Durrant, Ian, Luger, Selina M. , Marks, David I. , Franklin, Ian M., McMillan, Andrew , Tallman, Martin S. , Rowe, Jacob M. , Goldstone, Anthony H., Fielding, Adele K. , Lazarus, Hillard M. , Franklin, Ian M.

Mayo Clinic

Blood | October 10, 2006 | Volume: 109 | Issue: 3 | Pages: 944-950

10.1182/blood-2006-05-018192 | PMID 17032921 Get It

Abstract Most adults with acute lymphoblastic leukemia (ALL) who achieve complete remission (CR) will relapse. We examined the outcome of 609 adults with recurring ALL, all of whom were previously treated on the Medical Research Council (MRC) UKALL12/ECOG2993 study, where the overall survival (OS) of newly diagnosed patients is 38% (95% confidence interval [CI] = 36%-41%) at 5 years. By contrast, OS at 5 years after relapse was 7% (95% CI = 4%-9%). Factors predicting a good outcome after salvage therapy were young age (OS of 12% in patients younger than 20 years vs OS of 3% in patients older than 50 years; 2P < .001) and short duration of first remission (CR1) (OS of 11% in those with a CR1 of more than 2 years versus OS of 5% in those with a CR1 of less than 2 years; 2P < .001). Treatment received in CR1 did not influence outcome after relapse. In a very highly selected subgroup of patients who were able to receive HSCT after relapse, some were long-term survivors. We conclude from a large, unselected series with mature follow-up that most adults with recurring ALL, whatever their prior treatment, cannot be rescued using currently available therapies. Prevention of recurrence is the best strategy for long-term survival in this disease.
Carnitine Deficiency of Human Skeletal Muscle with Associated Lipid Storage Myopathy: A New Syndrome
Engel, Andrew G. , Angelini, C.

Mayo Clinic

Science | October 5, 2006 | Volume: 179 | Issue: 4076 | Pages: 899-902

10.1126/science.179.4076.899 | PMID 4687787 Get It

In a rare myopathy muscle fibers contained myriad lipid-filled vacuoles. Homogenates of the patient's muscle oxidized fatty acids more slowly than normal (11 controls). Addition of carnitine increased the oxidation rate with the patient's muscle to the level attained by the controls with carnitine. In five separate muscle samples from the patient the mean carnitine level was less than 20 percent of that observed in 42 controls. Carnitine palmityl transferase and palmityl thiokinase levels in the patient's muscles were not depressed. The present case represents the first recognized instance of carnitine deficiency in human skeletal muscle.
Vertebral Endplate Fractures: An Indicator of the Abnormal Forces Generated in the Spine After Vertebroplasty
Trout, Andrew T. , Kallmes, David F. , Layton, Kennith F. , Thielen, Kent R. , Hentz, Joseph G. , Trout, Andrew T

Mayo Clinic

Journal of Bone and Mineral Research | September 29, 2006 | Volume: 21 | Issue: 11 | Pages: 1797-1802

10.1359/jbmr.060723 | PMID 17002575 Get It

Abstract Vertebroplasty alters spinal biomechanics and may lead to incident vertebral fractures. The endplate localization of prevalent and incident fractures was evaluated in 86 patients. In the absence of vertebroplasty, superior endplate fractures predominate. After the procedure, inferior endplate fractures are disproportionately common in adjacent vertebrae immediately above the treated level, potentially supporting a causative relationship between vertebroplasty and incident fractures. Introduction: To determine retrospectively whether new-onset fractures after vertebroplasty tend to cluster in the endplate immediately adjacent to the cemented vertebra. Materials and Methods: Institutional Review Board approval and patient consent for use the use of medical records were obtained for this study. We performed a retrospective review of patients with new (incident) vertebral fractures after vertebroplasty. The median age for these patients was 72.5 years, and 58 (67.4%) were women. Fractures were diagnosed on the basis of MRI or bone scan and were catalogued based on their location within the vertebral body (superior endplate, inferior endplate, or holo-vertebral). χ2 and generalized estimating equation (GEE) analyses were used to compare the distribution of fracture subtypes among pre-existing (prevalent) and incident fractures. Results: The patients had 313 prevalent osteoporotic vertebral fractures and were treated at 137 vertebral levels. Among prevalent fractures, superior endplate fractures predominated (57% superior, 11% inferior; p &lt; 0.0001). After vertebroplasty, 186 incident fractures developed in these 86 patients. Seventy-seven (41%) of these incident fractures occurred adjacent to treated vertebrae. Nonadjacent, incident fractures, like prevalent fractures, occurred predominantly along superior endplate. Incident fractures immediately above treated levels, however, localized disproportionately to the inferior endplate (30% superior, 57% inferior; p &lt; 0.0001). Conclusions: There are an increased number of inferior endplate fractures of the vertebral body immediately cephalad to the treated level.
Health Outcomes Categorized by Current and Previous Definitions of Acute Myocardial Infarction in an Unselected Cohort of Troponin-Naïve Emergency Department Patients
Kavsak, Peter A. , MacRae, Andrew R., Newman, Alice, Ko, Dennis T. , Lustig, Viliam, Tu, Jack V. , Jaffe, Allan S. , Richards, C. Sue , Jaffe, Allan S. , Kavsak, Peter

Mayo Clinic

Clinical Chemistry | September 21, 2006 | Volume: 52 | Issue: 11 | Pages: 2028-2035

10.1373/clinchem.2006.073403 | PMID 16990413 Get It

Abstract Background: In a population originally classified for acute myocardial infarction (AMI) by the World Health Organization (WHO) definition, we compared the health outcomes after retrospectively reclassifying with the European Society of Cardiology and the American College of Cardiology (ESC/ACC) AMI definition, using the peak cardiac troponin I (cTnI) concentrations. The health outcomes were based on the WHO definition and occurred in an era that preceded the use of cardiac troponin biomarkers. Methods: For 448 patients who presented to the emergency department with symptoms suggestive of cardiac ischemia in 1996, we obtained data for all-cause mortality and recurrent AMI for up to 1 year after the initial presentation. We performed retrospective analysis of the patients’ frozen plasma samples to measure cTnI (AccuTnI®, Beckman Coulter). Results: At 30, 120, and 360 days, the risk for AMI/death in patients positive for AMI by only the ESC/ACC criteria was significantly lower than the risk in patients positive by both ESC/ACC and WHO criteria, and significantly higher than in patients negative according to both criteria. In a separate analysis, patients with a peak cTnI &gt;0.10 μg/L were at greater risk for AMI/death than patients with cTnI concentrations of 0.04–0.10 μg/L. Patients negative by both definitions or with peak cTnI concentrations &lt;0.04 μg/L had the highest event-free survival rates (92% and 94%, respectively) at 1 year. Conclusion: In a troponin-naïve population, patients classified as positive for AMI by only the ESC/ACC criteria have a prognosis that appears to be intermediate between those classified positive by both the WHO and ESC/ACC definitions and those who meet neither criteria.